Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Annuloplasty
SORIN GROUP: Announces U.S. FDA'S Authorization to Market Its Memo 3D(TM) Annuloplasty Ring in the United States
October 8th, 2007
The Sorin Group (MIL:SRN), the largest European cardiovascular company and world leader in medical technologies for cardiac surgery, announced that it has received the U.S. Food and Drug Administration's authorization for marketing its MEMO 3D Semirigid Annuloplasty Ring in the USA. Annuloplasty rings are indicated for repair of the mitral valve and are designed to remodel the anatomical shape of the mitral annulus, preventing further dilatation and minimizing the risk of late repair failures. "Due to its innovative core structure, the MEMO 3D ring restores the natural mitral annulus' three-dimensional motility during the cardiac cycle" said Franco...
Source: Biotech Business Week (2007-10-08)
|
